The latest price target for MoonLake (NASDAQ:MLTX) was reported by HC Wainwright & Co. on September 12, 2024. The analyst firm set a price target for $100.00 expecting MLTX to rise to within 12 months (a possible 85.05% upside). 37 analyst firms have reported ratings in the last year.

The latest analyst rating for MoonLake (NASDAQ:MLTX) was provided by HC Wainwright & Co., and MoonLake reiterated their buy rating.

There is no last upgrade for MoonLake

The last downgrade for MoonLake Immunotherapeutics happened on August 26, 2024 when Wolfe Research changed their price target from N/A to N/A for MoonLake Immunotherapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MoonLake, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MoonLake was filed on September 12, 2024 so you should expect the next rating to be made available sometime around September 12, 2025.

While ratings are subjective and will change, the latest MoonLake (MLTX) rating was a reiterated with a price target of $100.00 to $100.00. The current price MoonLake (MLTX) is trading at is $54.04, which is out of the analyst’s predicted range.